Will Medicare Pay for GLP-1 Drugs? (2026)

Direct Answer: Will Medicare Pay for Your GLP-1?

It depends on the diagnosis code on the prescription, not the drug name alone. Ozempic, Mounjaro, Trulicity, and Rybelsus get paid under standard 2026 Part D cost-sharing when prescribed for type 2 diabetes. Wegovy, Zepbound, and Foundayo get paid only when the cardiovascular-risk indication or the 2026-2027 Bridge Program applies; otherwise Medicare pays nothing and the full list price falls on you.

How Medicare Part D Payment Actually Works: The Three-Phase Structure

Original Medicare does not pay for self-administered drugs like GLP-1 injectables at all; Medicare Part A (hospital) and Medicare Part B (outpatient medical) only pay for drugs given in a clinical setting. Payment for a GLP-1 you pick up at a pharmacy flows exclusively through Medicare Part D, whether that is a standalone Part D plan paired with Original Medicare, or the drug portion of a Medicare Advantage plan (MAPD). Medigap supplements never touch drug costs, so a Medigap policy does nothing to lower a GLP-1 bill.

For 2026, every standard Part D plan follows the same three-phase payment structure that the Inflation Reduction Act of 2022 put in place starting in 2025. Phase one is the deductible: you pay 100% of the drug's negotiated price up to $615 before Medicare starts paying anything. Phase two is the initial coverage phase: Medicare's plan pays roughly 75% and you pay about 25% coinsurance on most brand drugs, continuing until your total out-of-pocket spending for the year hits $2,100. Phase three is catastrophic coverage: once you cross the $2,100 mark, your plan pays 100% and you pay $0 for covered drugs for the rest of the calendar year.

What You Actually Pay for Diabetes-Indicated GLP-1s in 2026

Ozempic, Mounjaro, Trulicity, and Rybelsus carry FDA-approved diabetes indications, so Medicare Part D treats a diabetes-diagnosed prescription like any other covered specialty drug. Plans typically place these drugs on a specialty formulary tier, which usually means the 25% coinsurance described above rather than a small flat copay. At an approximate 2026 list price of $998 for Ozempic or $1,080 for Mounjaro, your 25% coinsurance during the initial coverage phase runs roughly $250 to $270 per fill before you have even met your $2,100 out-of-pocket cap for the year.

Because specialty-tier coinsurance accumulates fast, most beneficiaries taking a diabetes GLP-1 every month reach the $2,100 catastrophic threshold within the first two to three fills of the year. After that, Medicare pays 100% of the negotiated price for the remaining months. Beneficiaries taking a diabetes GLP-1 alongside other high-cost drugs typically hit the cap even faster.

What You Actually Pay Under the Two Weight-Loss Payment Paths

Wegovy prescribed for cardiovascular-risk reduction follows the same three-phase math as any covered specialty drug: 100% of the price up to the $615 deductible, then roughly 25% coinsurance (about $335 per month at an approximate $1,349 list price) until you hit the $2,100 cap, then $0. Standard formulary rules, tiering, and appeal rights apply exactly as they would for a diabetes GLP-1.

The Bridge Program works differently on purpose: it operates outside the normal Part D payment flow entirely, using a single CMS-run central processor rather than your plan's usual claims system. The beneficiary copay is a flat $50 per month for Wegovy, Zepbound (KwikPen formulation only), or Foundayo, and that $50 never counts toward your deductible or your $2,100 out-of-pocket cap. The catch on payment mechanics: Part D sponsors are not required to opt in to the Bridge Program, so not every plan pays this way. Call your plan directly to confirm it has activated Bridge Program payment before assuming the $50 rate applies.

Prior Authorization: The Payment Gate Before Medicare Pays a Claim

Most Part D plans require prior authorization before they will pay a GLP-1 claim, meaning your doctor's office must submit documentation proving the diagnosis code matches a covered indication before the pharmacy can process payment. For diabetes claims, that usually means an A1C result and an E11 diagnosis code. For the Wegovy cardiovascular exception, plans typically want documentation of established coronary artery disease, prior heart attack, or prior stroke plus a BMI of 27 or higher, coded specifically for MACE risk reduction rather than obesity. Some plans also require step therapy, meaning you must have tried and failed a cheaper drug like metformin first before Medicare will pay for a GLP-1.

If prior authorization has not cleared, the pharmacy's claim gets rejected at the register and you are quoted the full cash price, sometimes over $1,000, even for a drug your plan would otherwise pay for. Ask your prescriber's office to submit prior authorization paperwork before you go to the pharmacy, and ask the pharmacy to run a test claim so you know the payment status before you commit to a fill.

If Medicare Won't Pay: How to Appeal a GLP-1 Payment Denial

A payment denial starts with a coverage determination from your Part D plan, which you or your doctor can request before or after a pharmacy rejects a claim. If the plan still says no, you have the right to file a redetermination, the first formal appeal level: standard requests get a decision within 7 days, and expedited requests (when waiting could seriously harm your health) get a decision within 72 hours. If the redetermination also fails, the case moves to an independent review entity, then an Administrative Law Judge hearing for claims above a dollar threshold, then the Medicare Appeals Council, and finally federal court.

A separate and often faster route is a formulary exception or tiering exception request, where your doctor argues the drug is medically necessary and asks the plan to cover it as if it were on a lower cost-sharing tier, or to waive a step-therapy requirement. This does not change whether the statutory weight-loss exclusion applies, but it can lower your coinsurance on an already-covered diabetes or CVD-indicated GLP-1.

Extra Help Lowers What You Pay for GLP-1s in 2026

The Low-Income Subsidy, known as Extra Help, changes the payment math entirely for beneficiaries who qualify. Everyone approved for Extra Help now receives the full subsidy level under the 2022 Inflation Reduction Act, which means a $0 Part D premium in most cases, a $0 deductible, and copay caps instead of 25% coinsurance: no more than $5.10 for a generic and $12.65 for a brand-name drug like Ozempic or Mounjaro in 2026. Full-benefit dual-eligible beneficiaries with income below the poverty level pay even less: $1.60 for generics and $4.90 for brand-name drugs.

Extra Help does not override the statutory weight-loss exclusion; it only lowers what you pay for a claim Medicare is already paying. If your GLP-1 is denied because it is prescribed solely for weight loss outside the two exceptions, Extra Help's copay caps do not apply because there is no Medicare-paid claim to cap in the first place.

Alternatives If Medicare Won't Pay for Your GLP-1

If your prescription falls outside every path Medicare pays through, five alternatives are worth exploring before accepting the full list price.

• Ask your doctor whether a covered diagnosis applies. If you have both diabetes and obesity, or both cardiovascular disease and obesity, documenting the covered diagnosis code (rather than obesity alone) can shift the same prescription onto a path Medicare pays.
• Manufacturer direct-pay cash programs. Novo Nordisk's NovoCare Pharmacy and Eli Lilly's LillyDirect sell GLP-1s at reduced self-pay prices, often in the $349 to $650 per month range depending on dose and product, without using insurance. These are cash-pay list prices, not manufacturer coupons, so federal healthcare program rules restricting copay coupons for Medicare beneficiaries generally do not block them.
• File a formulary or tiering exception. Even when a drug is technically excluded, a documented medical-necessity exception request occasionally succeeds where a routine claim would not, particularly for the CVD-indication pathway.
• Check state Medicaid if you are dual-eligible. Medicaid is not bound by the Part D anti-obesity exclusion, and several states already cover GLP-1s for obesity on their Medicaid formularies at Medicaid cost-sharing rates, often $0 to $4 per prescription.
• If you have not yet enrolled in Medicare, weigh marketplace timing. ACA-compliant marketplace plans must cover prescription drugs as one of the ten essential health benefits, and preexisting condition protections mean an insurer cannot deny a plan or charge more because of an obesity or diabetes history. This only matters for the enrollment-timing decision itself, not for someone already on Medicare.

Does Medicare Part D pay for Ozempic if I have diabetes?

Yes, under standard 2026 cost-sharing. Ozempic carries an FDA diabetes indication, so a diabetes-diagnosed prescription is a normal covered specialty drug: you pay up to $615 toward the deductible, then about 25% coinsurance (roughly $250/month at list price), then $0 once your out-of-pocket spending hits the $2,100 annual cap.

How much will I pay out of pocket for Mounjaro on Medicare in 2026?

For the diabetes indication, expect to pay 100% up to the $615 deductible, then roughly 25% coinsurance (about $270/month at an approximate $1,080 list price) until you reach the $2,100 out-of-pocket cap, after which Medicare pays 100% for the rest of the year. Mounjaro has no FDA weight-loss indication, so it does not qualify for the Bridge Program or the CVD exception.

Does the GLP-1 Bridge Program copay count toward my Part D deductible?

No. The Bridge Program's flat $50 per month copay for Wegovy, Zepbound KwikPen, or Foundayo does not count toward your Part D deductible or your $2,100 annual out-of-pocket cap. The Bridge Program processes payment outside the normal Part D claims flow through a CMS central processor, running July 1, 2026 through December 31, 2027.

What happens if my Part D plan denies payment for a GLP-1 drug?

You or your doctor can request a coverage determination, then file a redetermination if denied, the first formal appeal (7-day standard decision, 72-hour expedited). You can also request a formulary or tiering exception. If the redetermination fails, the case can proceed to an independent review entity, then an Administrative Law Judge, the Medicare Appeals Council, and federal court.

Do I need prior authorization before Medicare will pay for a GLP-1?

Almost always. Your doctor must submit documentation showing the diagnosis code matches a covered pathway, such as an A1C result for diabetes or documented cardiovascular disease plus BMI for Wegovy's CVD indication, before the pharmacy can process a paid claim. Without cleared prior authorization, the pharmacy will quote you the full cash price, often over $1,000.

Does Extra Help lower what I pay for GLP-1 drugs on Medicare?

Yes, if the drug is already on a path Medicare pays. Full-subsidy Extra Help enrollees pay no more than $5.10 for generics and $12.65 for brand-name drugs in 2026, or $1.60 and $4.90 respectively for full-benefit dual-eligible beneficiaries below the poverty level, instead of standard 25% coinsurance. Extra Help does not change whether a weight-loss-only prescription is covered at all.

Will every Medicare Part D plan pay through the Bridge Program?

Not necessarily. Part D sponsors are not required to opt into the GLP-1 Bridge Program, so some plans may not activate the $50/month payment path even though the eligible drugs and dates are federally set. Call your plan directly, or check the Medicare Plan Finder, to confirm your specific plan has opted in before assuming the $50 rate applies.

What if I'm prescribed a GLP-1 for both diabetes and weight loss?

Medicare pays based on the diagnosis code the claim is submitted under, not the reason you personally want the drug. If your doctor documents a covered diagnosis, like type 2 diabetes or established cardiovascular disease, Medicare pays under standard cost-sharing even though you may also be losing weight as a secondary benefit of the same prescription.